Does Michigan Medicaid cover GLP-1s for weight loss?
Does Michigan Medicaid cover GLP-1s for weight loss?
Michigan Medicaid covers GLP-1 receptor agonists for obesity, subject to prior authorization. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". The published threshold is: Classified as morbidly obese — the state's notice does not print a figure. On what has to be tried or preferred first: Documented failure of every other clinically appropriate weight-loss intervention, and trial and failure of the preferred anti-obesity agents on the PDL. For renewal: Approvals granted before 1 January 2026 ran out their six months by 30 June 2026; the new criteria have applied at every renewal since. Those criteria are quoted from Michigan Medicaid health plan bulletin on MDHHS notice L 25-73, read directly rather than summarized from an aggregator.
What Michigan changed, and when
- 2026-01-01 — Coverage kept, but narrowed to morbid obesity with documented failure of every other intervention and only to avert bariatric surgery the document that says so
What the prior authorization asks for
- BMI threshold
- Classified as morbidly obese — the state's notice does not print a figure
- Tried first
- Documented failure of every other clinically appropriate weight-loss intervention, and trial and failure of the preferred anti-obesity agents on the PDL
- To keep it
- Approvals granted before 1 January 2026 ran out their six months by 30 June 2026; the new criteria have applied at every renewal since
- Approval runs for
- 6 months, then a renewal request
Michigan also requires that the drug be used to avert bariatric surgery, which is the strictest condition any covering state on this page applies. The bulletin says the clinical prior-authorization criteria for GLP-1s prescribed only for weight loss were to be rewritten to match the legislation and posted on the MDHHS pharmacy site; the underlying notice is MDHHS L-letter L 25-73.
Both tools fill from these criteria rather than from a template — a prior authorization for Michigan, or a letter appealing a denial. If the plan is not Medicaid, the 9 insurer and program pages cover a different set of rules.
Whatever Michigan decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: Michigan Medicaid health plan bulletin on MDHHS notice L 25-73 , effective 2026-01-01. Read on 2026-09-05. Fee-for-service rules; a managed-care plan in Michigan can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.